Neurogene Provides Update on NGN-401 Gene Therapy Clinical Trial for Rett Syndrome

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. RNG
2. WDC
3. DECK
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. FIX

Go back to Neurogene Provides Update on NGN-401 Gene Therapy Clinical Trial for Rett Syndrome

Neurogene (NGNE) PT Lowered to $45 at BMO Capital

November 19, 2024 4:02 PM EST

BMO Capital analyst Keith Tapper lowered the price target on Neurogene (NASDAQ: NGNE) to $45.00 (from $60.00) while maintaining a Outperform rating.

The analyst comments "Neurogene shares are trading near cash on: 1) emerging SAE in a high-dose patient, consistent with overexposure/overdose of AAV9 or adenovirus... More